Analysts expect Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report sales of $32.14 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from $30.95 million to $34.00 million. Catalyst Pharmaceuticals reported sales of $29.14 million in the same quarter last year, which indicates a positive year over year growth rate of 10.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, May 10th.
According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full year sales of $134.24 million for the current fiscal year, with estimates ranging from $125.72 million to $138.10 million. For the next financial year, analysts anticipate that the business will post sales of $157.50 million, with estimates ranging from $132.48 million to $174.40 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Tuesday, March 16th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The firm had revenue of $31.02 million for the quarter, compared to analysts’ expectations of $30.06 million. Catalyst Pharmaceuticals had a return on equity of 35.04% and a net margin of 60.48%.
Catalyst Pharmaceuticals stock opened at $4.39 on Wednesday. Catalyst Pharmaceuticals has a 12 month low of $2.88 and a 12 month high of $5.19. The company has a market capitalization of $455.79 million, a PE ratio of 6.55 and a beta of 1.53. The stock has a 50-day moving average price of $4.21 and a two-hundred day moving average price of $3.72.
A number of large investors have recently bought and sold shares of CPRX. HealthInvest Partners AB bought a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at about $5,845,000. Royce & Associates LP grew its position in Catalyst Pharmaceuticals by 34.7% in the fourth quarter. Royce & Associates LP now owns 2,405,129 shares of the biopharmaceutical company’s stock worth $8,033,000 after acquiring an additional 620,239 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of Catalyst Pharmaceuticals by 139.0% during the fourth quarter. Nuveen Asset Management LLC now owns 916,829 shares of the biopharmaceutical company’s stock valued at $3,063,000 after buying an additional 533,282 shares during the period. Globeflex Capital L P purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $1,257,000. Finally, BlackRock Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 3.7% in the fourth quarter. BlackRock Inc. now owns 7,744,197 shares of the biopharmaceutical company’s stock valued at $25,866,000 after purchasing an additional 274,900 shares during the period. 64.86% of the stock is currently owned by institutional investors and hedge funds.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.
See Also: Quiet Period Expirations Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.